The stock has recovered smartly, and is now closing in on the higher end of the $36-$42 range. However, the volumes have not been too high. The resignation of the CEO had a negative impact on the stock, but rebound has been good. Analysts are also getting more positive on the stock, and consider it a good long term bet at current valuations. The expected improvement in fundamentals over the next few years is likely to be supported by the growth in the generics market. Generics comprise 51% of Teva's sales, and it will be able to increase sales even if it is able to maintain its market share. One analyst on seekingalpha stated that the loss in sales due to expiration of Copaxone patent is likely to be covered by other launches. The company recently got an Orphan designation for Treanda in indolent B-cell non-Hodgkin lymphoma. It has six months of pediatric exclusivity for the drug. Further, sales of ProAir and Qvar, will also help support growth. The R&D expenditure has been increased to support development of new products. Further, the company is expected to continue its focus on cost rationalization and efficiency. 70% of the benefits of these efforts will be achieved in the next three years, which will lead to improvement in margins. As per the analyst, 'this will help the company is cover up for the price erosion, volume growth and other factors.' The valuations are relatively reasonable, and the dividend yield is also good. Dr. Frost's leadership is encouraging, and he has been extremely active in exploring collaboration opportunities between the various companies which he controls. Cocrystal Discovery, a company where Teva and Opko (OPK) have a stake, recently merged with Biozone pharmaceuticals (BZNE) to take advantage of expected synergies. The real test for Teva is to move beyond the upper end of the range decisively.